{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:00:23Z","timestamp":1791291623094,"version":"4.1.0"},"reference-count":36,"publisher":"American Veterinary Medical Association (AVMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Objective<\/jats:bold>\u2014To determine the effect of protein binding on the pharmacokinetics and distribution from plasma to interstitial fluid (ISF) of cephalexin and cefpodoxime proxetil in dogs.<\/jats:p>\n<jats:p><jats:bold>Animals<\/jats:bold>\u20146 healthy dogs.<\/jats:p>\n<jats:p><jats:bold>Procedures<\/jats:bold>\u2014In a crossover study design, 25 mg of cephalexin\/kg or 9.6 mg of cefpodoxime\/kg was administered orally. Blood samples were collected before (time 0) and 0.33, 0.66, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after treatment. An ultrafiltration device was used in vivo to collect ISF at 0, 2, 4, 6, 8, 10, 12, 16, and 24 hours. Plasma and ISF concentrations were analyzed with high-pressure liquid chromatography. Plasma protein binding was measured by use of a microcentrifugation technique.<\/jats:p>\n<jats:p><jats:bold>Results<\/jats:bold>\u2014Mean plasma protein binding for cefpodoxime and cephalexin was 82.6% and 20.8%, respectively. Mean \u00b1 SD values for cephalexin in plasma were determined for peak plasma concentration (C<jats:sub>max<\/jats:sub>, 31.5 \u00b1 11.5 \u03bcg\/mL), area under the time-concentration curve (AUC, 155.6 \u00b1 29.5 \u03bcg\u2022h\/mL), and terminal half-life (T<jats:sub>\u00bd<\/jats:sub>, 4.7 \u00b1 1.2 hours); corresponding values in ISF were 16.3 \u00b1 5.8 \u03bcg\/mL, 878 \u00b1 21.0 \u03bcg\u2022h\/mL, and 3.2 \u00b1 0.6 hours, respectively. Mean \u00b1 SD values for cefpodoxime in plasma were 33.0 \u00b1 6.9 \u03bcg\/mL (C<jats:sub>max<\/jats:sub>), 282.8 \u00b1 44.0 \u03bcg\u2022h\/mL (AUC), and 5.7 \u00b1 0.9 hours (T<jats:sub>1\/2<\/jats:sub>); corresponding values in ISF were 4.3 \u00b1 2.0 \u03bcg\/mL, 575 \u00b1 174 \u03bcg\u2022h\/mL, and 10.4 \u00b1 3.3 hours, respectively.<\/jats:p>\n<jats:p><jats:bold>Conclusions and Clinical Relevance<\/jats:bold>\u2014Tissue concentration of protein-unbound cefpodoxime was similar to that of the protein-unbound plasma concentration. Cefpodoxime remained in tissues longer than did cephalexin.<\/jats:p>","DOI":"10.2460\/ajvr.71.12.1484","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T08:02:40Z","timestamp":1291190560000},"page":"1484-1491","source":"Crossref","is-referenced-by-count":32,"title":["Pharmacokinetics, protein binding, and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs"],"prefix":"10.2460","volume":"71","author":[{"given":"Mark G.","family":"Papich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Floerchinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"Comparison of the efficacy of cefadroxil and generic and proprietary cephalexin in the treatment of pyoderma in dogs","first-page":"530","volume":"203","author":"Frank","year":"1993"},{"key":"ref2","series-title":"Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study","first-page":"384","volume":"49","author":"Toma","year":"2008"},{"key":"ref3","series-title":"Cefadroxil: a new orally effective cephalosporin antibiotic","first-page":"339","volume":"79","author":"Chatfield","year":"1984"},{"key":"ref4","series-title":"Comparison of the efficacy of cefpodoxime proxetil and cephalexin in treating bacterial pyoderma in dogs","first-page":"85","volume":"4","author":"Cherni","year":"2006"},{"key":"ref5","series-title":"The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in Beagle dogs","first-page":"320","volume":"30","author":"Brown","year":"2007"},{"key":"ref6","series-title":"Effect of food on absorption of cefadroxl and cephalexin in dogs","first-page":"418","volume":"21","author":"Campbell","year":"1998"},{"key":"ref7","series-title":"Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular administration","first-page":"308","volume":"22","author":"Carli","year":"1999"},{"key":"ref8","series-title":"Antibiotic concentration in the serum of dogs and cats following a single oral dose of cephalexin","first-page":"106","volume":"115","author":"Crosse","year":"1984"},{"key":"ref9","series-title":"Metoclopramide modifies oral cephalexin pharmacokinetics in dogs","first-page":"127","volume":"30","author":"Prados","year":"2007"},{"key":"ref10","series-title":"Pharmacokinetics of two once-daily parenteral cephalexin formulations in dogs","first-page":"419","volume":"28","author":"Rebuelto","year":"2005"},{"key":"ref11","series-title":"Pharmacokinetics of cephalexin in dogs and cats after oral, subcutaneous, and intramuscular administration","first-page":"15","volume":"122","author":"Silley","year":"1988"},{"key":"ref12","series-title":"Animal model pharmacokinetics and pharmacodynamics: a critical review","first-page":"261","volume":"19","author":"Andes","year":"2002"},{"key":"ref13","series-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","first-page":"289","volume":"2","author":"Drusano","year":"2004"},{"key":"ref14","series-title":"Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations","first-page":"285","volume":"19","author":"Liu","year":"2002"},{"key":"ref15","series-title":"Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimization","first-page":"307","volume":"14","author":"AliAbadi","year":"2000"},{"key":"ref16","series-title":"Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs","first-page":"329","volume":"28","author":"Bidgood","year":"2005"},{"key":"ref17","series-title":"Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs","first-page":"1622","volume":"63","author":"Bidgood","year":"2002"},{"key":"ref18","series-title":"Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs","first-page":"1040","volume":"64","author":"Bidgood","year":"2003"},{"key":"ref19","series-title":"Challenges to antibiotic activity in tissue","first-page":"910","volume":"19","author":"Barza","year":"1994"},{"issue":"suppl D","key":"ref20","series-title":"Pharmacokinetics of antibiotics in shallow and deep compartments","first-page":"17","volume":"31","author":"Barza","year":"1993"},{"key":"ref21","series-title":"Antibiotic tissue concentrations: methodological aspects and interpretation of results","first-page":"7","volume":"44","author":"Cars","year":"1985"},{"key":"ref22","series-title":"Pharmacokinetics of antibiotics in tissues and tissue fluids: a review","first-page":"23","volume":"74","author":"Cars","year":"1991"},{"key":"ref23","series-title":"Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning","first-page":"1947","volume":"35","author":"Nix","year":"1991"},{"key":"ref24","series-title":"Effect of ratio of surface area to volume on the penetration of antibiotics into extravascular spaces in an in vitro mode","first-page":"423","volume":"146","author":"Van Etta","year":"1982"},{"key":"ref25","series-title":"Tissue concentrations: do we ever learn?","first-page":"235","volume":"61","author":"Mouton","year":"2008"},{"key":"ref26","series-title":"Distribution of oxytetracycline to tissue cages and granuloma pouches in calves and effect of acute inflammation on distribution to tissue cages","first-page":"385","volume":"14","author":"Bengtsson","year":"1991"},{"key":"ref27","series-title":"Tissue-chamber modeling systems\u2014applications in veterinary medicine","first-page":"349","volume":"12","author":"Clarke","year":"1989"},{"key":"ref28","series-title":"Subcutaneously implanted tissue chamber\u2014a pharmacokinetic study","first-page":"312","volume":"12","author":"Clarke","year":"1989"},{"key":"ref29","series-title":"Pharmacokinetic\/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine","first-page":"503","volume":"27","author":"McKellar","year":"2004"},{"key":"ref30","series-title":"Staphylococcus pseudintermedius","first-page":"1569","volume":"55","author":"Devriese","year":"2005"},{"key":"ref31","series-title":"Antimicrobial activity and spectrum of cefovecin, a new extended-spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America","first-page":"2286","volume":"50","author":"Stegemann","year":"2006"},{"key":"ref32","series-title":"General chapter on validation on compendial procedures","year":"2008"},{"key":"ref33","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"ref34","series-title":"Tissue penetration of cefpodoxime and cefixime in healthy subjects","first-page":"564","volume":"45","author":"Liu","year":"2005"},{"issue":"suppl E","key":"ref35","series-title":"The pharmacokinetics of the oral cephalosporins\u2014a review","first-page":"13","volume":"26","author":"Wise","year":"1990"},{"key":"ref36","series-title":"The pharmacodynamics of \u03b2-lactams","first-page":"10","volume":"27","author":"Turnidge","year":"1998"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/71\/12\/ajvr.71.12.1484.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/71\/12\/ajvr.71.12.1484.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/71\/12\/ajvr.71.12.1484.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:23:05Z","timestamp":1741350185000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/71\/12\/ajvr.71.12.1484.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":36,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.71.12.1484","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}